A novel experimental drug for early Parkinson's disease (PD) yielded similar results as commercially available pramipexole extended-release (ER) but with significantly less daytime sleepiness, a new ...
The fixed-dose combination therapy was found to be superior to each component. A phase 3 study evaluating a novel fixed-dose combination of extended release (ER) formulations of pramipexole and ...
Patients with Parkinson disease demonstrated significant reduction in depressive symptoms with citalopram and pramipexole, with pramipexole showing slightly more benefit in improving quality of life.
Pramipexole dihydrochloride extended-release 0.375mg, 0.75mg, 1.5mg, 2.25mg, 3mg, 3.75mg, 4.5mg; tabs. Swallow whole. May take with food. Initially 0.375mg once daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results